Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | RO6874281 |
| Trade Name | |
| Synonyms | RG 7461|RG7461|Simlukafusp alfa|RO-6874281 |
| Drug Descriptions |
RO6874281 (Simlukafusp alfa) is a fusion protein consists of a human anti-fibroblast activation protein-alpha (FAP) antibody and an engineered interleukin-2, which may stimulate local immune response against FAP-positive tumor cells (NCI Drug Dictionary). |
| DrugClasses | |
| CAS Registry Number | 1776942-10-9 |
| NCIT ID | C129383 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atezolizumab + Bevacizumab + Obinutuzumab + RO6874281 | Atezolizumab Bevacizumab Obinutuzumab RO6874281 | 0 | 1 |
| Atezolizumab + Obinutuzumab + RO6874281 | Atezolizumab Obinutuzumab RO6874281 | 0 | 1 |
| Atezolizumab + RO6874281 | Atezolizumab RO6874281 | 0 | 1 |
| Cetuximab + RO6874281 | Cetuximab RO6874281 | 0 | 0 |
| Pembrolizumab + RO6874281 | Pembrolizumab RO6874281 | 0 | 1 |
| RO6874281 | RO6874281 | 0 | 1 |